AMARIN CORP PLC\UK Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for the quarter ending 2020-09-30 was -$28.00K.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for the quarter ending 2020-06-30 was -$238.00K.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for the quarter ending 2018-12-31 was $0.00.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for the quarter ending 2018-09-30 was -$39.00K.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for fiscal 2020 was -$504.00K.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for fiscal 2018 was -$39.00K.
- AMARIN CORP PLC\UK stock issued during period, value, conversion of convertible securities for fiscal 2015 was -$187.00K.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2020-12-31 | -$504.00K 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$28.00K 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$238.00K 10-Q · filed 2021-11-03 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$39.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | -$39.00K 10-Q · filed 2019-11-05 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$187.00K 10-K · filed 2018-02-27 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |